NASDAQ: ALECAlector Inc Stock
$1.53-0.04 (-2.55%)
Updated Jun 12, 2026
ALEC Price
$1.53
Fair Value Price
-$0.03
Market Cap
$169.87M
52 Week Low
$1.09
52 Week High
$3.40
P/E
-1.29x
P/B
16.36x
P/S
12.91x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.42M
Earnings
-$125.39M
Gross Margin
100%
Operating Margin
-679.92%
Profit Margin
-680.8%
Debt to Equity
22.11
Operating Cash Flow
-$173M
Beta
1.71
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ALEC Overview
Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering new treatments for neurodegenerative disorders. A key program in its pipeline is AL001, a humanized recombinant monoclonal antibody currently undergoing Phase III clinical trials. This investigational therapy targets a range of severe conditions, including frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Additionally, AL101 is progressing through Phase I clinical trials for general neurodegenerative diseases, with a specific focus on Alzheimer's and Parkinson's. Further bolstering its Alzheimer's portfolio, Alector is evaluating AL002 in Phase II studies and AL003 in Phase I studies, both aimed at addressing Alzheimer's disease. In earlier-stage development, the company is also developing AL044, which targets the MS4A4A gene, identified as a risk factor for Alzheimer's disease. Alector has forged key partnerships to advance its mission. It collaborates with Adimab, LLC on antibody research and development. Furthermore, a significant strategic alliance with GlaxoSmithKline plc (GSK) focuses on the joint development and commercialization of monoclonal antibodies, specifically AL001 and AL101, for neurodegenerative conditions. Established in 2013, Alector's headquarters are located in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALEC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ALEC
Ranked#69 of 463
Ranked#69 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important ALEC news, forecast changes, insider trades & much more!
ALEC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALEC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALEC ($1.53) is overvalued by 5,387.93% relative to our estimate of its Fair Value price of -$0.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALEC ($1.53) is not significantly undervalued (5,387.93%) relative to our estimate of its Fair Value price of -$0.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALEC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALEC due diligence checks available for Premium users.
Valuation
ALEC fair value
Fair Value of ALEC stock based on Discounted Cash Flow (DCF)
Price
$1.53
Fair Value
-$0.03
Undervalued by
5,387.93%
ALEC ($1.53) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALEC ($1.53) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALEC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALEC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.29x
Industry
16.53x
Market
14.15x
ALEC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
16.36x
Industry
4.85x
ALEC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALEC's financial health
Profit margin
Revenue
$1.0M
Net Income
-$22.9M
Profit Margin
-2,192.2%
ALEC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ALEC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$239.9M
Liabilities
$229.5M
Debt to equity
22.11
ALEC's short-term assets ($215.08M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALEC's short-term assets ($215.08M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALEC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ALEC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$49.8M
Investing
$60.9M
Financing
$25.0k
ALEC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALEC vs Biotech Stocks
Alector Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.